Keli Therapeutics

Executive Summary

Keli Therapeutics is a Berlin-based preclinical-stage biotech developing two cell therapy platforms: autologous chondrocyte technology for knee pain and allogeneic immunomodulatory stem cells for inflammatory diseases. Founded in 2017, the company leverages proprietary cell engineering to address large unmet needs in orthopedics and chronic inflammation. Its autologous approach aims to improve cartilage repair outcomes, while the allogeneic platform offers off-the-shelf potential for broad immunosuppression. Despite being early-stage with no disclosed funding or pipeline specifics, Keli's dual-platform strategy differentiates it in the competitive cell therapy landscape. Success hinges on preclinical validation and progress toward first-in-human studies.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data in Inflammatory Disease Model60% success
• H1 2027IND/CTA Filing for First Clinical Trial40% success
• 2026Strategic Partnership or Licensing Deal for Allogeneic Platform30% success